Thomson Reuters Names Most Promising Drugs of 2015

Annual forecast finds significant increase in the number of blockbusters set to enter this year's market

News provided by

Mar 23, 2015, 12:01 ET

PHILADELPHIA, March 23, 2015 /PRNewswire/ -- The Intellectual Property and Science business of Thomson Reuters, the world's leader in intelligent information for businesses and professionals, today released the 2015 edition of its annual Drugs to Watch report. The study reveals a significant increase in the number of expected blockbusters from three drugs in 2014 to eleven in 2015. Three of the new drugs are expected to reach more than $3 billion in sales by 2019. Thomson Reuters analysts utilized Cortellis^™ Competitive Intelligence—the pharmaceutical industry's leading source for drug pipeline, deals, patents, and company content—to forecast the new-to-market drugs expected to lead the pack in sales and potentially emerge as blockbusters (earning $ 1 billion+) by 2019.

The analysis spotlights the following 11 potential blockbusters, ranked by highest sales forecasts:

Drugs to Watch	Company	Therapy Area	2019 Sales Forecast in U.S. $ billions)
Opdivo (nivolumab)	Bristol-Myers Squibb	Melanoma	5.684
Praluent (alirocumab)	Regeneron Pharmaceuticals and Sanofi	Hypercholesterolemia	4.414
LCZ-696 (sacubitril and valsartan)	Novartis	chronic heart failure	3.731
Ibrance (palbociclib)	Pfizer	breast cancer	2.756
lumacaftor plus ivacaftor	Vertex Pharmaceuticals	cystic fibrosis	2.737
Viekira Pak (veruprevir, ritonavir, ombitsvir and dasabuvir)	AbbVie	hepatitis C	2.500
evolocumab	Amgen and Astellas Pharma	hypercholesterolemia/ hypherlipidemia	1.862
Gardasil 9	Merck & Co.	HPV Vaccine	1.637
brexpiprazole	Otsuka Pharmaceutical and Lundbeck	schizophrenia and depression	1.353
Toujeo (new-formulation insulin glargine)	Sanofi	Diabetes	1.265
Cosentyx (secukinumab)	Novartis	psoriasis and psoriatic arthritis	1.082

"This year's forecast identifies a substantial increase in the number of predicted blockbusters, inviting discussion around the current status of the blockbuster model," said Wendy Hamilton, global head of Life Sciences at Thomson Reuters. "As the pharmaceutical industry navigates constantly evolving revenue streams, this report serves as a valuable resource for identifying the therapies with the strongest sales potential."

To learn more about the year's most promising treatments, view 2015 Drugs to Watch. Learn more about Cortellis for Competitive Intelligence.

Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. For more information, go to www.thomsonreuters.com.

Jen Breen
+1 215 823 1791
[email protected]

Molly Malone
+1 215 823 3702
[email protected]

SOURCE Thomson Reuters